INSULIN DETEMIR

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20590743 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021536s031s051lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/25667307

Insulin detemir, a long-acting human insulin analog, is sold under the brand name LEVEMIR to improve glycemic control in adults and children with diabetes mellitus. Insulin detemir binds to the insulin receptor. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and by inhibiting the output of glucose from the liver. The primary activity of insulin detemir is the regulation of glucose metabolism. Insulin detemir crosses the BBB and reduces food intake, it improves weight management by an enhanced and prolonged centrally mediated reduction of energy intake.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Insulin receptor 13 Target ID: P06213 Gene ID: 3643.0 Gene Symbol: INSR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20590743 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021536s031s051lbl.pdf	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
diabetes mellitus 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021536s031s051lbl.pdf	Palliative		Approved 8583	LEVEMIR Approved Use Levemir is indicated to improve glycemic control in adults and children with diabetes mellitus. Launch Date 2005

PubMed

Title	Date	PubMed
COMPARISON OF EFFICACY AND SAFETY OF GLARGINE AND DETEMIR INSULIN IN THE MANAGEMENT OF INPATIENT HYPERGLYCEMIA AND DIABETES.	2017-09	28683239
Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor.	2010-08	20590743
Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin.	2008-09	18585815
Tissue selectivity of insulin detemir action in vivo.	2006-06	16570163

Sample Use Guides

In Vivo Use Guide

LEVEMIR (Insulin detemir) is a recombinant human insulin analog for once- or twice-daily subcutaneous administration. Patients treated with LEVEMIR once-daily should administer the dose with the evening meal or at bedtime. Patients who require twice-daily dosing can administer the evening dose with the evening meal, at bedtime, or 12 hours after the morning dose. The dose of LEVEMIR must be individualized based on clinical response. Blood glucose monitoring is essential in all patients receiving insulin therapy

Route of Administration: Other

Name

Type

Language

INSULIN DETEMIR

Official Name

English

INSULIN DETEMIR RECOMBINANT

Preferred Name

English

INSULIN B29(N-MYRISTOYL-LYS)-B30(DES-THR) HUMAN RECOMBINANT

Common Name

English

LEVEMIR

Brand Name

English

29(SUP B)-(N(SUP 6)-(1-OXOTETRADECYL)-L-LYSINE)-(1(SUP A)-21(SUP A)),(1(SUP B)-29(SUP B))-INSULIN (HUMAN)

Common Name

English

INSULIN,DETEMIR,HUMAN [VANDF]

Common Name

English

INSULIN DETEMIR [USAN]

Common Name

English

29(SUP B)-(N(SUP 6)-MYRISTOYL-L-LYSINE)-30(SUP B)-DE-L-THREONINEINSULIN (HUMAN)

Common Name

English

DETEMIR

Common Name

English

N.EPSILON.B29-TETRADECANOYL DES(B30) HUMAN INSULIN

Common Name

English

INSULIN,DETEMIR,HUMAN

Common Name

English

INSULIN DETEMIR [EMA EPAR]

Common Name

English

(1A-21A),(1B-29B)-INSULIN (HUMAN), 29B-(N6-(1-OXOTETRADECYL)-L-LYSINE)-, RECOMBINANT

Common Name

English

INSULIN DETEMIR [MI]

Common Name

English

insulin detemir [INN]

Common Name

English

INSULIN DETEMIR RECOMBINANT [ORANGE BOOK]

Common Name

English

NN-304

Code

English

INSULIN DETEMIR [JAN]

Common Name

English

Insulin detemir [WHO-DD]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175453